Discussion Forums > Working Towards a Cure
JAK2 inhibitor
love and prayers:
brilliant! i'll post the status of the trials in a bit.
love and prayers:
Could you please look at this:
http://www.emdchemicals.com/life-science-research/jak2-inhibitor-iii-sd-1029/EMD_BIO-573098/p_WkSb.s1O7mcAAAErMhkqPdBL
Andy Battaglia:
I believe that the products listed here are for sale for research purposes and are not intended for prescription purposes. I would not recommend self experimentation with this. Until thorough trials have been completed to rule out any unforeseen problems with the drug, it is never wise to use it.
love and prayers:
Found 10 clinical trials with JAK2 inhibitors
Rank Status Study
1 Active, not recruiting This is a Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor in Patients With Multiple Myeloma Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma
Intervention: Drug: INCB018424 Phase II
2 Recruiting Study of INCB018424 for Acute Leukemia Condition: Leukemia
Intervention: Drug: INCB018424 Phase I Phase II
3 Recruiting Open Label INCB018424 in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Conditions: Myelofibrosis; Polycythemia Vera; Thrombocytosis
Intervention: Phase I Phase II
4 Recruiting Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases Conditions: Primary Myelofibrosis (PMF); Post-Polycythaemia Vera; Essential Thrombocythaemia Myelofibrosis
Intervention: Drug: AZD1480 Phase I Phase II
5 Recruiting A Study in Patients With Rheumatoid Arthritis on Background Methotrexate Therapy Condition: Arthritis, Rheumatoid
Interventions: Drug: LY3009104; Drug: Placebo Phase II
6 Active, not recruiting A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Conditions: Myelofibrosis; Myeloproliferative Disorders; Polycythemia Vera; Essential Thrombocythemia
Intervention: Drug: SB1518 Phase I Phase II
7 Active, not recruiting A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies Conditions: Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Myelofibrosis
Intervention: Drug: SB1518 Phase I Phase II
9 Recruiting A Study of AZD1480 in Asian Patients With Advanced Solid Malignancies and Asian Patients With Advanced Hepatocellular Carcinoma Conditions: Advanced Solid Malignancies; Child-Pugh A to B7 Advanced Hepatocellular Carcinoma; Solid Cancer Refractory to Standard Therapies; Liver Cancer Refractory to Standard Therapies With Mild and Moderate Liver Function
Intervention: Drug: AZD1480 Phase I
10 Recruiting A Single and Multiple-Dose Study of SB1578 Condition: Healthy Volunteer
Interventions: Drug: SB1578; Drug: Placebo Phase I
love and prayers:
YM BioSciences Reports Positive Updated Anemia Response Data for its JAK1/JAK2 Inhibitor CYT387 Disclosed at First Annual Florence Meeting on Myeloproliferative Neoplasms in Florence, Italy
PR Newswire
MISSISSAUGA, ON, April 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were disclosed by Dr. Ayalew Tefferi (Mayo Clinic, Rochester, Minnesota), Chair of the Study, during the First Annual Florence Meeting on Myeloproliferative Neoplasms held in Florence, Italy on Saturday, April 16th, 2011.
"These results continue to highlight the potential for CYT387 to induce durable anemia responses, as demonstrated using these more rigorous measurement standards," said Dr. Nick Glover, President and CEO of YM BioSciences. "We look forward to reporting updated interim data on CYT387's safety and efficacy profile at the ASCO conference in June."
Dr. Tefferi reported that the overall anemia response rate was 58% in 33 transfusion-dependent patients. In this assessment, anemia response required a transfusion-free period of ≥12 weeks while on protocol drug therapy, with a minimum hemoglobin level of 8 g/dL. The median duration of transfusion independence was reported to be 6 months (range 4-15 months). Only 2 (11%) of the 19 patients who achieved transfusion-independency were reported to require single episodes of PRBC transfusions.
The results were based on data observed for the first 60 patients enrolled in the dose escalation (n=21) and dose confirmation (n=39) portions of the 140 patient Phase I/II trial, for which recruitment has now been exceeded. These 60 high/intermediate-risk myelofibrosis patients have received CTY387 orally once daily in 28-day cycles, and have completed a minimum of 3 cycles of treatment.
About CYT387:
CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, and as well in numerous other disorders including indications in hematology, oncology and inflammatory diseases. Myelofibrosis is a chronic debilitating disease in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CYT387 for the treatment of myelofibrosis.
YM BioSciences retains full global commercialization rights to CYT387.
For more information on the CYT387 Phase I/II trial, go to:
http://clinicaltrials.gov/ct2/show/NCT00935987?term=cyt387&rank=1
About YM BioSciences
YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).
CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in various Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE YM BioSciences Inc.
Copyright 2010 PR Newswire. All Rights Reserved
Navigation
[0] Message Index
[#] Next page
[*] Previous page
Go to full version